Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis

Italian Journal of Gastroenterology and Hepatology

Volumn 29, Issue 3, 1997, Pages 262-266

  Borzio, M ^a,c   Salerno, F ^b   Saudelli, M ^a   Galvagno, D ^a   Piantoni, L ^a   Fragiacomo, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c Ospedale Falebenefratelli   (Italy)

Author keywords

Ciprofloxacin; Cirrhosis; Intestinal decontamination

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT; DRUG EFFICACY; ESCHERICHIA COLI; FECES; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; INTESTINE INFECTION; KLEBSIELLA OXYTOCA; LIVER CIRRHOSIS; MALE; ORAL DRUG ADMINISTRATION; STREPTOCOCCUS GROUP D;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; CIPROFLOXACIN; FECES; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 0031444378     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rimola A, Soto R, Arroyo V, Fiera C, Rodes J. Reticuloendotheliae system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984;4:53-8.
2. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing, and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986;6:252-62.
3. Such J, Guarner C, Enriquez J, Rodriguez JL, Seres I, Vilardell F. Low C3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. J Hepatol 1988;6:80-4.
4. Wyke RJ. Problems of bacterial infection in patients with liver disease. Gut 1987;28:623-41.
5. Runyon BA. Spontaneous bacterial peritonitis: an explosion of information. Hepatology 1988;8:171-5.
6. Van Der Waaij D, Berghuids JM, Lekkenkert JEC. Colonization resistance of the digestive tract of mice during systemic antibiotic treatment. J Hyg (London) 1972;70:605-10.
7. Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: double-blind placebo-controlled trial. Hepatology 1990;12:716-24.
8. Soriano G, Guamer C, Teixido M, Such J, Barrios J, Enriquez J, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100:477-81.
9. Soriano G, Guamer C, Tomas A, Villanueva C, Torras X, Gonzales D, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992:103:1267-72.
10. Rozemberg-Arska M, Dekker AW, Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dis 1985;152:104-7.
11. Dennig D, Fülle H, Hellriegel KP. Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin. Onkologie 1987;10:57-8.
12. De Witte T, Novakova I, Branolte J, Muytiens H, De Pauw B. Long-term oral ciprofloxacin for infection prophylaxis in allogenic bone marrow transplantation. Pharmaceutisch Weekblad 1987;9(suppl.):48-50.
13. Rolanchon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995;22:1171.
14. Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistence in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Ag Chemother 1994;38:340.
15. Sutler VL, Citrin DM, Edelstein MAC, Finegold SM. Wadsworth anaerobic bacteriology manual, 4th ed. California: Star Publishing, 1986.
16. Hodelman LV, Moore WEC, editors. Anaerobic laboratory manual, 4th ed. Blacksburg: Virginia Polytechnic Institute and State University, 1975.
17. Pecquet S, Ravoire S, Andremont A. Faecal excretion of ciprofloxacin after a single dose and its effect on faecal bacteria in healthy volunteers. J Antimicrob Chemother 1990;26:125-9.
18. Bow EJ, Ronald AR. Editorial: Antibacterial chemoprophylaxis in neutropenic patients - where do we g'o from here? Clin Infect Dis 1993;17:333-7.
19. Van der Amwera P, Gérai J. Use of quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients. Drugs 1993;45(S3):81-90.
20. Lliovet JM, Rodriguez-Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M, et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997;26:88-95.
21. Daum TE, Schaberg DR, Terpenning MS, Sottile \VS, Kauffman CA. Increasing resistance of staphylococcus aureus to ciprofloxacin. Antimicrob Ag Chemother 1990;34:1862-3.
22. Raeburn JA, Govan JRW, McCrae WM, Greening AP, Collier PS, Hodson ME, et al. Ciprofloxacin therapy in cystic fibrosis. J Antimicrob Chemother 1987;20:295-6.